Suven Life Sciences is all set to present two scientific presentations highlighting the clinical progress of its investigational drug candidates, Masupirdine (SUVN-502) and Tenaclidine (SUVN-I6107), at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, taking place during, November 16-19, 2026, at Boston, USA.
Masupirdine, a Pure 5-HT6 Receptor Antagonist: Baseline Demographic and Clinical Characteristics of the Phase-3 Clinical Study Targeting Agitation in Patients with Dementia of Alzheimer’s Type - Baseline demographic and clinical characteristics of patients enrolled in the global Phase-3 study of Masupirdine will be presented.
Tenaclidine, a Pure M1 Positive Allosteric Modulator First-in-Human Evaluation of Safety, Tolerability and Pharmacokinetics in Healthy Subjects - Outcome from the Phase-1 single ascending dose (SAD) and multiple ascending dose (MAD) studies of Tenaclidine (SUVN-I6107) in healthy subjects, including safety, tolerability and pharmacokinetics, as well as the effects of food, age and gender on its pharmacokinetic profile will be presented.
CTAD is a global forum dedicated exclusively to Alzheimer’s disease clinical research, bringing together investigators, clinicians, industry scientists, and regulatory experts committed to advancing the field. CTAD fosters a collective scientific experience, encourages in-depth dialogue, and creates meaningful interactions across disciplines and offers an opportunity to engage with key opinion leaders, clinical trial specialists, regulatory representatives, and multidisciplinary research teams, while gaining insight into the latest advances shaping prevention and treatment strategies.
Suven Life Sciences provides wide range of Drug Discovery and Development Support Services (DDDSS) to global Pharma and Biotech companies. It has state-of-art facilities with highly qualified & experienced team of scientists.